<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750447</url>
  </required_header>
  <id_info>
    <org_study_id>1035</org_study_id>
    <nct_id>NCT04750447</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of an Ab Interno Gelatin Stent (XEN63) With or Without Mitomycin C</brief_title>
  <official_title>Safety and Efficacy of an Ab Interno Gelatin Stent (XEN63) With or Without Mitomycin C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prism Eye Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Prism Eye Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Xen gelatin microstent (Allergan, CA, USA) is a 6mm hydrophobic, bleb-forming&#xD;
      microinvasive glaucoma surgery (MIGS).1 Creation of a filtering bleb through the gel stent&#xD;
      and under the conjunctiva lowers intraocular pressure (IOP) by bypassing the natural outflow&#xD;
      pathway of aqueous. Currently three Xen models have been developed: 45, 63, and 140 um&#xD;
      internal lumen diameters.2 XEN45 ab interno gelatin stent was the first to be approved for&#xD;
      clinical use in Canada.3 A recent retrospective cohort study showed comparable safety and&#xD;
      risk of failure to trabeculectomy.4 Amongst the main advantages of this device is the ability&#xD;
      to create a bleb without dissecting and disrupting tissue, thus decreasing the amount of&#xD;
      wound healing and potentially limiting bleb failure. Recently, the XEN63 ab interno gelatin&#xD;
      stent was approved by Health Canada for clinical use in Canada. Being a new device, to date,&#xD;
      no study has examined the effect of XEN63 ab interno gelatin stent on anti-glaucoma drops&#xD;
      burden and IOP. The aim of this study is to investigate the safety and efficacy of the XEN63&#xD;
      ab interno gelatin stent to provide insights for ophthalmologists who will want to add this&#xD;
      technique to their practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      • This is a prospective, single-arm, open-label clinical trial designed to demonstrate the&#xD;
      safety and IOP-lowering effectiveness of XEN 63. Approximately 29 patients who are scheduled&#xD;
      to undergo glaucoma surgery with XEN63 implantation will be enrolled and followed for up to&#xD;
      12 months postoperatively. Enrollees will follow the standard of care visits (pre-op, post-op&#xD;
      day 1, post-op week 1 and post op month 1) where they will undergo a full eye exam (visual&#xD;
      acuity, refraction, slit lamp exam and intraocular pressure measurement). In addition to the&#xD;
      standard of care visit, enrollees will have 2 additional visits (post-op month 6 and post-op&#xD;
      month 12) where they will undergo a full eye exam. Additional tests include a Visual Field&#xD;
      assessment and Endothelial cell count on their pre-op visit, post-operative month visit 6 and&#xD;
      post-op month 12 visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">December 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 9, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Complete Success</measure>
    <time_frame>1 month post op to post op month 12</time_frame>
    <description>Intraocular Pressure: 6-17 mmHg and on no glaucoma medications at least 1 month after surgery with no reoperation using the Goldmann Applanation Tonometer..</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of complications</measure>
    <time_frame>post op day 1 to post op month 12</time_frame>
    <description>Absence of the following complications as reported during slitlamp examination:&#xD;
i. Starting after POM1: shallow AC w/ iridocorneal touch, any hyphema, corneal edema, choroidal effusion, malignant glaucoma, dellen/non-healing epithelial defect, ptosis, diplopia.&#xD;
ii. At any point: additional glaucoma surgery, loss of light perception vision, vitreous hemorrhage, ≥2mm hyphema, hypotony maculopathy, implant migration/blockage/exposure/extrusion, macular edema, choroidal effusion/hemorrhage requiring drainage, suprachoroidal hemorrhage, retinal detachment, blebitis/endophthalmitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Qualified Success</measure>
    <time_frame>post op month 1 to post op month 12</time_frame>
    <description>a. 'Complete success' criteria except that Intraocular Pressure (IOP) can be above IOP thresholds, and then reduced to within the 'Complete criteria' by medications or laser in 3 visits or less as measured by Goldmann Applanation Tonometry.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Open Angle Glaucoma</arm_group_label>
    <description>Patients aged 30-90 Primary open angle glaucoma on maximum tolerated medical therapy Going to receive XEN63 ab interno gelatin stent with or without MMC in study eye ± cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XEN 63</intervention_name>
    <description>The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.</description>
    <arm_group_label>Open Angle Glaucoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled to undergo Xen 63 implantation for open angle glaucoma with or without&#xD;
        cataract surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 30-90 Primary open angle glaucoma on maximum tolerated medical therapy&#xD;
             Going to receive XEN63 ab interno gelatin stent with or without MMC in study eye ±&#xD;
             cataract surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other forms of glaucoma&#xD;
&#xD;
          -  Previous glaucoma shunt/valve in the target quadrant of study eye&#xD;
&#xD;
          -  Presence of conjunctival scarring, prior conjunctival surgery or other conjunctival&#xD;
             pathologies (e.g., pterygium) in the target quadrant of study eye&#xD;
&#xD;
          -  Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis), active&#xD;
             iris neovascularization or neovascularization of the iris within six months of the&#xD;
             surgical date&#xD;
&#xD;
          -  Presence of anterior chamber intraocular lens, intraocular silicone oil, vitreous&#xD;
             present in the anterior chamber, impaired episcleral venous drainage (e.g.,&#xD;
             Sturge-Weber or nanophthalmos or other evidence of elevated venous pressure)&#xD;
&#xD;
          -  Known or suspected allergy or sensitivity to drugs required for the surgical procedure&#xD;
             or any of the device components (e.g., porcine products or glutaraldehyde), history of&#xD;
             dermatologic keloid formation.&#xD;
&#xD;
          -  Prior CPC, corneal graft (PKP, DALK, DSAEK, DMEK)&#xD;
&#xD;
          -  Other forms of combined surgery (cornea, retina) besides cataract surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Iqbal Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prism Eye Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronaldo Santiago, MD</last_name>
    <phone>905-4563937</phone>
    <phone_ext>267</phone_ext>
    <email>ronaldo.santiago@prismeye.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ramzi Jumaa, MD</last_name>
    <phone>905-456-3937</phone>
    <phone_ext>267</phone_ext>
    <email>ramzi3@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prism Eye Institute</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 0J8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronaldo Santiago, MD</last_name>
      <phone>(905) 456-3937</phone>
      <phone_ext>267</phone_ext>
      <email>ike.research@prismeye.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Conlon R, Saheb H, Ahmed II. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017 Feb;52(1):114-124. doi: 10.1016/j.jcjo.2016.07.013. Epub 2016 Nov 17. Review.</citation>
    <PMID>28237137</PMID>
  </reference>
  <reference>
    <citation>Green W, Lind JT, Sheybani A. Review of the Xen Gel Stent and InnFocus MicroShunt. Curr Opin Ophthalmol. 2018 Mar;29(2):162-170. doi: 10.1097/ICU.0000000000000462. Review.</citation>
    <PMID>29319544</PMID>
  </reference>
  <reference>
    <citation>Schlenker MB, Gulamhusein H, Conrad-Hengerer I, Somers A, Lenzhofer M, Stalmans I, Reitsamer H, Hengerer FH, Ahmed IIK. Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation versus Standalone Trabeculectomy. Ophthalmology. 2017 Nov;124(11):1579-1588. doi: 10.1016/j.ophtha.2017.05.004. Epub 2017 Jun 7. Erratum in: Ophthalmology. 2018 Mar;125(3):463.</citation>
    <PMID>28601250</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prism Eye Institute</investigator_affiliation>
    <investigator_full_name>Iqbal Ahmed</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

